Skip to main content
EOLS
NASDAQ Life Sciences

Evolus Renews $250M Universal Shelf Registration for Future Capital Raises

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.67
Mkt Cap
$439.251M
52W Low
$3.86
52W High
$10.62
52W Position info
73% above low
Off High info
37% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

EOLS sits 73% above its 52-week low of $3.86.

Summary

Evolus filed a universal shelf registration statement for up to $250 million in various securities, replacing an expiring shelf and carrying forward $195.5 million in unsold capacity.


Key Events · Financing and Capital Events · EOLS

  • Universal Shelf Registration Filed

    Evolus filed an S-3 registration statement for the potential issuance of up to $250 million in common stock, preferred stock, debt securities, warrants, units, and rights.

  • Renewal of Expiring Program

    This S-3 replaces a previous registration statement (File No. 333-270370) that was set to expire on June 7, 2026.

  • Carried Forward Capacity

    The new registration carries forward $195,519,553 of unsold securities from the expiring shelf.

  • Future Dilution Potential

    The registration authorizes the company to issue an additional $54,480,447 in new securities, bringing the total potential offering capacity to $250 million.


Analysis · EOLS · Life Sciences

This S-3 filing is a routine renewal of Evolus's universal shelf registration, allowing the company to raise capital "from time to time" over the next three years. While it doesn't represent an immediate offering, it provides flexibility for future financing needs. The total authorized amount of $250 million is substantial relative to the company's market capitalization, representing significant potential dilution if fully utilized. This follows recent positive financial news, including positive Adjusted EBITDA and the termination of a previous ATM program, suggesting the company is proactively securing long-term financing options rather than facing immediate distress. Investors should watch for subsequent 424B prospectus supplements, which would detail actual offerings and their terms.

At the time of this filing, EOLS was trading at $6.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $439.3M. The 52-week trading range was $3.86 to $10.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EOLS - Latest Insights

EOLS
Jul 08, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $5.55 info
Change: -$1.30 (-19%) info
Market Cap: $365.165M info
EOLS
May 04, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.55 info
Change: -$0.0676 (-1%) info
Market Cap: $365.165M info
EOLS
May 04, 2026, 4:24 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $5.55 info
Change: -$0.235 (-4%) info
Market Cap: $365.165M info
EOLS
May 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.65
Real-time Price: $5.55 info
Change: -$0.105 (-2%) info
Market Cap: $365.165M info
EOLS
Mar 03, 2026, 5:01 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.91
Real-time Price: $5.55 info
Change: +$0.635 (+13%) info
Market Cap: $365.165M info